{"id":81620,"date":"2025-08-14T07:25:12","date_gmt":"2025-08-14T07:25:12","guid":{"rendered":"https:\/\/www.newsbeep.com\/us\/81620\/"},"modified":"2025-08-14T07:25:12","modified_gmt":"2025-08-14T07:25:12","slug":"opus-genetics-announces-financial-results-for-second-quarter-2025-and-provides-product-pipeline-updates","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us\/81620\/","title":{"rendered":"Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Product Pipeline Updates"},"content":{"rendered":"


\n
\n \"\"
\nRESEARCH TRIANGLE PARK, N.C.\u2014Opus Genetics, Inc.<\/a> (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, yesterday announced financial results for the second quarter ended June 30, 2025, and provided a corporate update. Net loss for the second quarter of 2025 was $7.4 million compared with a net loss of $7.8 million for the same period in 2024. License and collaboration revenue totaled $2.9 million for the second quarter of 2025, compared with $1.1 million in the same period in 2024, the company reported.<\/p>\n

Revenue in both periods was driven by the company\u2019s license and collaboration agreement with Viatris, Inc. largely from the reimbursement of research and development services, Opus Genetics said.\u00a0<\/p>\n

\u201cWe\u2019ve made significant progress across our pipeline, with multiple clinical and regulatory milestones achieved this quarter,\u201d said George Magrath, MD, chief executive officer, Opus Genetics. \u201cReceiving RMAT designation for our OPGx-LCA5 program underscores the strength of our clinical data and the urgent need for effective gene therapies to treat inherited retinal diseases. We are encouraged by the sustained functional vision improvements observed in adult patients in our clinical trial to date and the early signs of efficacy in the pediatric cohort. In parallel, our advancement of OPGx-BEST1 toward the clinic and the nomination of two additional development candidates in partnership with the Retinal Degeneration Fund and the Global RDH12 Alliance highlight the breadth of our IRD pipeline.\u201d<\/p>\n

He added, \u201cBeyond gene therapy, the positive readouts from our two Phase 3 Phentolamine trials represent a major step toward our goal of bringing a new treatment option to millions of patients living with vision challenges. With several upcoming key milestones, including new clinical data, a supplemental New Drug Application (sNDA) submission, and the launch of a pivotal study, we remain focused on execution to deliver transformative treatments to patients with significant unmet needs.\u201d<\/p>\n

General and administrative expenses were $5.8 million for the second quarter of 2025, compared with $3.4 million for the same period in 2024. R&D expenses were $6.0 million for the second quarter of 2025, compared with $6.1 million in the prior-year period. The slight decrease was primarily due to lower manufacturing and consulting costs, the company said, partially offset by increased clinical trial, toxicology, and payroll-related expenses.<\/p>\n

As of June 30, 2025, Opus Genetics had cash and cash equivalents of $32.4 million. Based on current operating plans, the company expects its existing cash resources will fund operations into the second half of 2026.
\n \n <\/p>\n","protected":false},"excerpt":{"rendered":" RESEARCH TRIANGLE PARK, N.C.\u2014Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for…\n","protected":false},"author":2,"featured_media":81621,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[50],"tags":[200,57101,79],"class_list":["post-81620","post","type-post","status-publish","format-standard","has-post-thumbnail","category-genetics","tag-genetics","tag-latest-news-eyecare-business-financial-opus-genetics-retinal-disease-viatris-inc-george-magrath-inherited-retinal-diseases-clinical-milestones","tag-science"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/81620","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=81620"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/81620\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/81621"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=81620"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=81620"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=81620"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}